Your browser is no longer supported. Please, upgrade your browser.
Settings
GHSI Guardion Health Sciences, Inc. daily Stock Chart
GHSI [NASD]
Guardion Health Sciences, Inc.
Index- P/E- EPS (ttm)-0.24 Insider Own7.23% Shs Outstand78.63M Perf Week1.77%
Market Cap44.90M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float79.69M Perf Month21.61%
Income-11.80M PEG- EPS next Q- Inst Own1.70% Short Float4.16% Perf Quarter24.73%
Sales0.90M P/S49.89 EPS this Y22.50% Inst Trans-43.26% Short Ratio0.34 Perf Half Y159.31%
Book/sh0.17 P/B3.11 EPS next Y- ROA- Target Price- Perf Year-68.88%
Cash/sh0.15 P/C3.48 EPS next 5Y- ROE- 52W Range0.17 - 3.05 Perf YTD140.12%
Dividend- P/FCF- EPS past 5Y-40.90% ROI-87.50% 52W High-82.66% Beta-
Dividend %- Quick Ratio11.80 Sales past 5Y40.60% Gross Margin60.60% 52W Low220.61% ATR0.05
Employees94 Current Ratio12.50 Sales Q/Q0.00% Oper. Margin- RSI (14)58.04 Volatility9.52% 9.53%
OptionableNo Debt/Eq0.00 EPS Q/Q52.50% Profit Margin- Rel Volume0.83 Prev Close0.52
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume9.67M Price0.53
Recom- SMA208.12% SMA5015.07% SMA20043.18% Volume8,016,369 Change0.95%
May-14-20 07:00AM  Guardion Health Sciences Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire -6.83%
May-12-20 07:05AM  Lumega-Z® Demonstrates Superiority in a Head-to-Head Study Showing Better Bioavailability of Carotenoids and Restoring Macular Pigment Density GlobeNewswire
Apr-15-20 09:05AM  Guardion Health Sciences to Present at the April 2020 Virtual Investor Summit GlobeNewswire -11.16%
Apr-14-20 11:00AM  Guardion Health Sciences Announces Launch of acuMMUNE: An Immuno-Supportive/Anti-Oxidant Complex GlobeNewswire
Apr-01-20 07:00AM  Guardion Health Sciences Receives Initial Order from Malaysian Company for Exclusive Immuno-Supportive Formula GlobeNewswire -6.62%
Mar-30-20 09:00AM  Guardion Health Sciences Reports 2019 Year End Results and Provides Corporate Update and Overview GlobeNewswire -7.09%
Mar-19-20 12:05PM  Guardion Health Sciences Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule GlobeNewswire
Mar-06-20 08:05AM  Guardion Health Sciences Receives $3.5 Million from Exercise of Warrants GlobeNewswire
Feb-26-20 07:00AM  Guardion Health Sciences Selected by Malaysian Listed Company to Develop an Immuno-Supportive Formula GlobeNewswire
Feb-06-20 07:00AM  Guardion® Announces Development of Unique Immuno-Supportive Complex Targeting Upper Respiratory Tract Infections GlobeNewswire +13.93%
Jan-07-20 11:02AM  Guardion® Appoints Experienced Executive to Lead Development and Expansion of Recently-Acquired NutriGuard Business Line GlobeNewswire -8.11%
Nov-14-19 07:00AM  Guardion Health Sciences, Inc. Reports Results for the Three and Nine Months Ended September 30, 2019 GlobeNewswire -8.52%
Oct-30-19 12:33PM  Guardion Health Sciences Closes $8.4 Million Underwritten Public Offering GlobeNewswire
Oct-28-19 09:21AM  Guardion Health Sciences Announces Pricing of $8.4 Million Underwritten Public Offering GlobeNewswire -34.80%
Oct-23-19 07:00AM  Guardion® Receives approval from USPTO for expanded claims for its Proprietary Medical Device, the MAPCAT SF GlobeNewswire
Oct-17-19 10:40AM  Here's Why We're A Bit Worried About Guardion Health Sciences's (NASDAQ:GHSI) Cash Burn Situation Simply Wall St.
Oct-10-19 10:30AM  Guardion® Announces Statistically Significant Blood Assay Study Results GlobeNewswire +5.10%
Sep-23-19 10:30AM  Guardion Health Sciences Acquires the NutriGuard Brand of Products GlobeNewswire +20.13%
Sep-03-19 02:08PM  Best & worst performing IPOs in 2019 Yahoo Finance Video
07:00AM  Guardion Launches VectorVision CSV-2000 Standardized Contrast Sensitivity Test GlobeNewswire
Aug-15-19 04:05PM  Guardion Health Sciences Closes $5.8 Million Underwritten Public Offering GlobeNewswire
08:35AM  Guardion Health Sciences Announces an Increase in the Pricing of its Previously Announced Underwritten Public Offering GlobeNewswire
Aug-13-19 09:00AM  Guardion Health Sciences Announces Pricing of $5.2 Million Underwritten Public Offering GlobeNewswire -59.66%
Aug-12-19 08:40AM  Guardion Health Sciences Reports June 30, 2019 Interim Results of Operations GlobeNewswire -8.49%
Aug-06-19 07:00AM  Foundation Fighting Blindness selects Guardions VectorVision CSV-1000 Diagnostic Instrument for Use in Large-Scale Multi-Center Clinical Trial GlobeNewswire
Jul-19-19 02:47PM  What Type Of Shareholder Owns Guardion Health Sciences, Inc.'s (NASDAQ:GHSI)? Simply Wall St.
Jul-17-19 07:00AM  Guardions Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents Registry GlobeNewswire +93.75%
Jun-20-19 07:00AM  Guardions Proprietary Medical Device, the MapcatSF®, Receives Patent from the European Union GlobeNewswire +7.23%
Jun-04-19 07:00AM  Guardion Launches Second Ocular Health Formula GlaucoCetin GlobeNewswire +24.84%
May-09-19 10:14AM  Guardions Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Function (CSF) vs AREDS 2 GlobeNewswire
May-07-19 07:00AM  Guardion's Lumega-Z Formula Associated with Improved Vision in Patients with Severe Glaucoma GlobeNewswire
May-01-19 07:00AM  Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China GlobeNewswire +6.36%
Apr-17-19 09:01AM  Results of Lumega-Z Data to be Presented at ARVO GlobeNewswire -12.00%
Apr-11-19 09:18AM  WallachBeth Capital Announces Completion of the $5 Million IPO for Guardion Health Services PR Newswire
Apr-09-19 12:20PM  Guardion Health Sciences, Inc. Announces Closing of Initial Public Offering GlobeNewswire -7.04%
Apr-05-19 12:49PM  Guardion Health Sciences, Inc. Announces Pricing of Initial Public Offering Business Wire
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Medical Devices. The Medical Foods segment offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. The Medical Devices segment offers VectorVision, which develops, manufactures, and sells equipment and supplies for standardized vision testing for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing; CSV-1000, an instrument for contrast sensitivity, glare sensitivity, low contrast acuity, and early treatment diabetic retinopathy; CSV-2000, a digital standardized contrast sensitivity testing device; and MapcatSF, a medical device that measures the macular pigment optical density. The company distributes its products through sales force, as well as through its guardionhealth.com Website. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.